```
                 T25FW: Percentage change from Part 1 baseline to each scheduled efficacy visit in Part 2
                                Subgroup Analysis: Confirmed Progression of disability
                                                    ITT population

                                                Confirmed Progressors
_____


                                                   Placebo to            Natalizumab
                                               Natalizumab 300 mg            300 mg                    p-value (a)
_____



Percentage change from Baseline to Week 156
   n                                                   156                     135
   Mean                                              127.05                  113.51                      0.4957
   SD                                               195.138                 160.857



_____
(a)p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for
baseline EDSS (<=5.5 or>=6) and baseline T25FW.
```

T25FW: Percentage change from Part 1 baseline to each scheduled efficacy visit in Part 2
Subgroup Analysis: Confirmed Progression of disability
ITT population

Non Progressors

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Percentage change from Baseline to Week 156			
n	99	129	
Mean	-5.68	-4.37	0.2916
SD	21.708	25.050	

(a)p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for baseline EDSS (<=5.5 or>=6) and baseline T25FW.